16 research outputs found

    Character education in New Zealand schools

    Full text link

    Character education in schools : a follow-up study

    Full text link

    Security Data Warehouse Application

    Get PDF
    The Security Data Warehouse (SDW) is used to aggregate and correlate all JSC IT security data. This includes IT asset inventory such as operating systems and patch levels, users, user logins, remote access dial-in and VPN, and vulnerability tracking and reporting. The correlation of this data allows for an integrated understanding of current security issues and systems by providing this data in a format that associates it to an individual host. The cornerstone of the SDW is its unique host-mapping algorithm that has undergone extensive field tests, and provides a high degree of accuracy. The algorithm comprises two parts. The first part employs fuzzy logic to derive a best-guess host assignment using incomplete sensor data. The second part is logic to identify and correct errors in the database, based on subsequent, more complete data. Host records are automatically split or merged, as appropriate. The process had to be refined and thoroughly tested before the SDW deployment was feasible. Complexity was increased by adding the dimension of time. The SDW correlates all data with its relationship to time. This lends support to forensic investigations, audits, and overall situational awareness. Another important feature of the SDW architecture is that all of the underlying complexities of the data model and host-mapping algorithm are encapsulated in an easy-to-use and understandable Perl language Application Programming Interface (API). This allows the SDW to be quickly augmented with additional sensors using minimal coding and testing. It also supports rapid generation of ad hoc reports and integration with other information systems

    Uma relação concreta: A prática do futebol em São Paulo e os Estádios do Parque Antarctica e do Pacaembu

    No full text
    Ao relacionar a introdução do futebol na cidade de São Paulo, seu desenvolvimento e a atração de torcedores, o artigo procura mostrar como esta prática esportiva tornou-se não apenas cultural, mas também material na Pauliceia. De maneira específica, o artigo analisa como dois dos principais estádios paulistanos foram forjados, e como as arquiteturas do Parque Antarctica, na Água Branca, e do Pacaembu, no bairro homônimo, possibilitaram o desenvolvimento e a celebração de uma tecnologia construtiva: a do concreto armado. O artigo explora, então, alguns caracteres de identidade da capital paulista: o futebol e o concreto armado, tecendo considerações sobre esta relação indelével, embora pouco explorada em nossa historiografia

    Pharmacological modulation of connexin-formed channels in cardiac pathophysiology

    No full text
    Coordinated electrical activity in the heart is supported by gap junction channels located at the intercalated discs of cardiomyocytes. Impaired gap junctional communication between neighbouring cardiomyocytes contributes to the development of re-entry arrhythmias after myocardial ischaemia. Current antiarrhythmic therapy is hampered by a lack of efficiency and side effects, creating the need for a new generation of drugs. In this review, we focus on compounds that increase gap junctional communication, thereby increasing the conduction velocity and decreasing the risk of arrhythmias. Some of these compounds also inhibit connexin 43 (Cx43) hemichannels, thereby limiting adenosine triphosphate loss and volume overload following ischaemia/reperfusion, thus potentially increasing the survival of cardiomyocytes. The compounds discussed in this review are: (i) antiarrythmic peptide (AAP), AAP10, ZP123; (ii) GAP-134; (iii) RXP-E; and (vi) the Cx mimetic peptides Gap 26 and Gap 27. None of these compounds have effects on Na+, Ca2+ and K+ channels, and therefore have no proarrhythmic activity associated with currently available antiarrhythmic drugs. GAP-134, RXP-E, Gap 26 and Gap 27 are pharmalogical agents with a favorable clinical safety profile, as already confirmed in phase I clinical trials for GAP-134. These agents show an excellent promise for treatment of arrhythmias in patients with ischaemic cardiomyopathy
    corecore